Literature DB >> 21455712

Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.

A Kirby, C Edwards, C M Broughton, N J Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21455712     DOI： 10.1007/s15010-011-0103-y

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  15 in total

1.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Jean B Patel; Laura A Jevitt; Jeffery Hageman; L Clifford McDonald; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2006-06-01       Impact factor: 9.079

Review 2.  Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.

Authors:  S J van Hal; D L Paterson; I B Gosbell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-30       Impact factor: 3.267

3.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

4.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

5.  Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents.

Authors:  Brian T Tsuji; Michael J Rybak; Chrissy M Cheung; Muhammad Amjad; Glenn W Kaatz
Journal:  Diagn Microbiol Infect Dis       Date:  2007-02-14       Impact factor: 2.803

Review 6.  Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.

Authors:  Pamela A Moise; Donald North; Judith N Steenbergen; George Sakoulas
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

7.  Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus.

Authors:  Jeffrey C Hageman; Jean Patel; Patrick Franklin; Karen Miscavish; Linda McDougal; David Lonsway; Fazle N Khan
Journal:  Diagn Microbiol Infect Dis       Date:  2008-10-07       Impact factor: 2.803

8.  Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales.

Authors:  M J Ellington; C Perry; M Ganner; M Warner; I McCormick Smith; R L Hill; L Shallcross; S Sabersheikh; A Holmes; B D Cookson; A M Kearns
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-05-30       Impact factor: 3.267

Review 9.  VanA-type vancomycin-resistant Staphylococcus aureus.

Authors:  Bruno Périchon; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

10.  Intermediate vancomycin susceptibility in a community-associated MRSA clone.

Authors:  Christopher J Graber; Margaret K Wong; Heather A Carleton; Françoise Perdreau-Remington; Barbara L Haller; Henry F Chambers
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883
View more
  2 in total

1.  Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy.

Authors:  B Preiswerk; A Rudiger; J Fehr; N Corti
Journal:  Infection       Date:  2012-07-21       Impact factor: 3.553

2.  Wound healing activity and mechanisms of action of an antibacterial protein from the venom of the eastern diamondback rattlesnake (Crotalus adamanteus).

Authors:  Ramar Perumal Samy; Matheswaran Kandasamy; Ponnampalam Gopalakrishnakone; Bradley G Stiles; Edward G Rowan; David Becker; Muthu K Shanmugam; Gautam Sethi; Vincent T K Chow
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.